Vol 1, No 3 (September 17, 2012): Translational Andrology and Urology

Editorial

PIVOT and the challenges of localized prostate cancer care

Aviva E. Weinberg, James D. Brooks

PDF Pages: 141-143 Full Text (6689) Open Access

New prognostic models in metastatic renal cancer

Louise Lim, Tom Powles

PDF Pages: 144-145 Full Text (4286) Open Access

Interpretation of PIVOT findings

Sergey Shikanov

PDF Pages: 146-147 Full Text (3003) Open Access

Original Article

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?

Sherif Azab, Ayman Osama, Mona Rafaat

PDF Pages: 148-152 Full Text (42383) Open Access

Review Article

Vesicoureteral reflux and bladder dysfunction

Hyeyoung Lee, Yong Seung Lee, Young Jae Im, Sang Won Han

PDF Pages: 153-159 Full Text (15356) Open Access

Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences

Mikio Namiki, Satoru Ueno, Yasuhide Kitagawa

PDF Pages: 160-172 Full Text (16425) Open Access

Regenerative technology for future therapy of erectile dysfunction

Ji-Kan Ryu, Jun-Kyu Suh

PDF Pages: 173-180 Full Text (12399) Open Access

Phytotherapy: emerging therapeutic option in urologic disease

Sae Woong Kim

PDF Pages: 181-191 Full Text (18194) Open Access

Research Highlight

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?

Zsuzsanna Mihály, Alexisz Panajotu, Balázs Győrffy

PDF Pages: 192-193 Full Text (3210) Open Access

The complexity of sunitinib dosing in renal cell cancer patients

Ingrid M.E. Desar, Sasja F. Mulder, Peter F.A. Mulders, Carla M.L. van Herpen

PDF Pages: 194-196 Full Text (4996) Open Access

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?

Marine Gross-Goupil, Alain Ravaud

PDF Pages: 197-198 Full Text (3503) Open Access